Cargando…

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

BACKGROUND: Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic resistance or develop acquired resistance. Here, we evaluated the mechanisms underlying acquired resistance to PDX and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oiwa, Kana, Hosono, Naoko, Nishi, Rie, Scotto, Luigi, O’Connor, Owen A., Yamauchi, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325835/ https://www.ncbi.nlm.nih.gov/pubmed/34332580 http://dx.doi.org/10.1186/s12885-021-08607-9

Ejemplares similares

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers
por: Scotto, Luigi, et al.
Publicado: (2020)

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
por: Kinahan, Cristina, et al.
Publicado: (2020)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance
por: Li, Fenglin, et al.
Publicado: (2022)

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
por: Yamauchi, Takahiro, et al.
Publicado: (2014)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Establishment and Characterization of a Newly Established Diabetic Gerbil Line
por: Li, Xiaohong, et al.
Publicado: (2016)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Establishment and Characterization of Carboplatin-Resistant Retinoblastoma Cell Lines
por: Cho, Chang Sik, et al.
Publicado: (2022)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway
por: Weng, Wanwen, et al.
Publicado: (2022)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

Establishment and characterization of methylmercury-resistant PC12 cell line.
por: Miura, K, et al.
Publicado: (1994)

3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis
por: Araie, Hiroaki, et al.
Publicado: (2017)

Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization.
por: Rockett, J. C., et al.
Publicado: (1997)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Establishment of Drug Resistance in Human Gastric and Colon Carcinoma Xenograft Lines
por: Satta, Tetsuya, et al.
Publicado: (1991)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest
por: Scotto, Luigi, et al.
Publicado: (2020)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines
por: UCHIBORI, KAZUYA, et al.
Publicado: (2011)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

Establishment and characterization of a docetaxel-resistant human prostate cancer cell line
por: Liu, Jian, et al.
Publicado: (2020)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Araie, Hiroaki, et al.
Publicado: (2023)

Antigenicity of newly established colorectal carcinoma cell lines.
por: Durrant, L. G., et al.
Publicado: (1986)

Loss of pyrethroid resistance in newly established laboratory colonies of Aedes aegypti
por: Vera-Maloof, Farah Z., et al.
Publicado: (2020)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

Biological and genetic characterization of a newly established human external auditory canal carcinoma cell line, SCEACono2
por: Komune, Noritaka, et al.
Publicado: (2023)

Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia
por: Ookura, Miyuki, et al.
Publicado: (2018)

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
por: Izbicka, E., et al.
Publicado: (2009)

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts
por: Tedeschi, Philip M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rmmktsjd3na3ec9jqagkalous8